SynCore Biotechnology Co.,Ltd

Equities

4192

TW0004192000

Biotechnology & Medical Research

End-of-day quote Taipei Exchange Other stock markets 18:00:00 2024-05-27 EDT			5-day change	1st Jan Change
44.55 ^TWD	+1.02%		-0.34%	+16.02%

03-19	SynCore Biotechnology Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	SynCore Biotechnology Co.,Ltd Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

Syncore Biotechnology Co., Ltd. announced that it expects to receive TWD 324 million in funding

July 23, 2018

Syncore Biotechnology Co., Ltd. (GTSM:4192) announced a private placement of 13,500,000 shares at a price of TWD 24 share for gross proceeds of TWD 324,000,000 on July 24, 2018. The transaction will close on August 2, 2018.

Latest news about SynCore Biotechnology Co.,Ltd

SynCore Biotechnology Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	03-19	CI
SynCore Biotechnology Co.,Ltd Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
SynCore Biotechnology Co.,Ltd Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11	CI
SynCore Biotechnology Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI
SynCore Biotechnology Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-06	CI
SynCore Biotechnology Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-06	CI
SynCore Biotechnology Co.,Ltd Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-10	CI
SynCore Biotechnology Co.,Ltd Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-11	CI
SynCore Biotechnology Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-11	CI
SynCore Biotechnology Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-07	CI
SynCore Biotechnology Co.,Ltd Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-09	CI
Syncore Biotechnology Co.,Ltd Reports Earnings Results for the Second Quarter Ended June 30, 2021	21-08-10	CI
Syncore Biotechnology Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2021	21-05-11	CI
Syncore Biotechnology Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2020	21-03-22	CI
Syncore Biotechnology Co.,Ltd Reports Earnings Results for the Third Quarter Ended September 30, 2020	20-11-09	CI
Syncore Biotechnology Co.,Ltd Reports Earnings Results for the Second Quarter Ended June 30, 2020	20-08-11	CI
Syncore Biotechnology Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2020	20-05-12	CI
Syncore Biotechnology Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2019	20-02-23	CI
Syncore Biotechnology Co.,Ltd Reports Earnings Results for the Third Quarter Ended September 30, 2019	19-11-10	CI
Syncore Biotechnology Co.,Ltd Reports Earnings Results for the Second Quarter Ended June 30, 2019	19-08-11	CI
Syncore Biotechnology Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2019	19-05-13	CI
Syncore Biotechnology Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2018	19-02-25	CI
Syncore Biotechnology Co., Ltd. Reports Earnings Results for the Third Quarter Ended September 30, 2018	18-11-11	CI
Syncore Biotechnology Co., Ltd. announced that it expects to receive TWD 324 million in funding	18-07-23	CI
Syncore Biotechnology Co., Ltd. announced a financing transaction	18-02-05	CI

Chart SynCore Biotechnology Co.,Ltd

Duration

Period

More charts

Company Profile

SynCore Biotechnology Co.,Ltd is a Taiwan-based company principally engaged in the research, development, production and sales of therapeutic drugs. The Company's main product is SB03 Veregen. The Company is also involved in research, development and clinical trials of the injection-type anticancer drug, SB01 and the oral anticancer drug, SB01. The Company distributes its products mainly in domestic market.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
SYNCORE BIOTECHNOLOGY CO.,LTD	+16.02%	48.65M
VERTEX PHARMACEUTICALS INCORPORATED	+9.83%	115B
REGENERON PHARMACEUTICALS, INC.	+10.80%	105B
BIONTECH SE	-10.84%	22.71B
ARGENX SE	-1.08%	21.83B
GENMAB A/S	-10.46%	18.18B
WUXI APPTEC CO., LTD.	-41.92%	16.52B
BEIGENE, LTD.	-15.11%	16.01B
NEUROCRINE BIOSCIENCES, INC.	+6.62%	14.14B
SAREPTA THERAPEUTICS, INC.	+17.53%	10.71B

Bio Therapeutic Drugs